Inclusion Criteria:

          1. ≥ 18 years old at the time of informed consent

          2. Ability to provide written informed consent and HIPAA authorization

          3. Untreated locally advanced Pancreatic Ductal Adenocarcinoma (PDAC) as defined by
             National Comprehensive Cancer Network (NCCN) guidelines or, untreated metastatic PDAC
             (prior adjuvant therapy is permitted if it's been greater than 6 months since
             completion)

          4. Histologically or cytologically confirmed PDAC

          5. Confirmed PDAC that is measurable or evaluable per RECIST 1.1

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          7. Gastrointestinal symptoms (nausea, vomiting, and diarrhea) of Grade 1 or less

          8. Adequate organ function as defined by:

               1. Aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x upper
                  limits of normal (ULN)

               2. Total bilirubin level ≤ 1.5 x ULN

               3. Creatinine level < 1.0 x ULN or creatinine clearance > 60 mL/min/1.73 m2 for
                  patients with creatinine levels above or below the institutional normal (as
                  determined by Cockcroft-Gault equation). For patients with a Body Mass Index
                  (BMI) > 30 kg/m2, lean body weight should be used to calculate the glomerular
                  filtration rate (GFR).

               4. Hemoglobin (Hgb) ≥ 9 g/dl

               5. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               6. Platelets ≥ 100 x 109/L

               7. Acceptable coagulation studies as demonstrated by prothrombin time (PT) within
                  normal limits (+/-15%) unless they are on anticoagulation therapy

          9. Life expectancy estimated at ≥ 3 months

         10. Women of childbearing potential definition (WOCBP) must have a negative serum or urine
             pregnancy test performed within 14 days prior to initiation of study treatment.

             Any woman (regardless of sexual orientation, having undergone a tubal ligation, or
             remaining celibate by choice) is classified as WOCBP if she meets the following
             criteria:

               1. Has not undergone a hysterectomy or bilateral oophorectomy; or

               2. Has not been naturally postmenopausal for at least 24 consecutive months (i.e.
                  has had menses at any time in the preceding 12 consecutive months).

         11. WOCBP and men must agree to use adequate contraception prior, to study entry, for the
             duration of study participation, and 8 weeks after the end of treatment.

        Exclusion Criteria:

          1. Neuropathy > Grade 1 at baseline

          2. Prior systemic chemotherapy for any other malignancy (aside from adjuvant therapy for
             PDAC) in the last 3 years

          3. Active malignancy other than PDAC (other than adequately treated cervical or vulvar
             carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial
             bladder tumors (Ta, Tis & T1), ductal carcinoma in situ (DCIS) of the breast and low
             grade prostate cancer. Any cancer curatively treated >3 years prior to entry with no
             clinical evidence of recurrence is permitted)

          4. Prior exposure to nab-paclitaxel, paclitaxel, or other taxanes

          5. History of bowel obstruction in the preceding 3 months of therapy, including gastric
             outlet obstruction related to PDAC

          6. Large, uncontrolled ascites requiring paracentesis

          7. Major surgery, other than diagnostic or laparoscopic surgery, within 4 weeks prior to
             first dose. (Port placement would not be considered a surgery.)

          8. Any known untreated brain metastases including leptomeningeal metastases

          9. Pregnant or breastfeeding

         10. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal
             Investigator, prevent absorption of an orally available agent (e.g., Crohn's disease,
             ulcerative colitis, extensive gastric resection, and small intestinal resection)

         11. Uncontrolled chronic diarrhea > Grade 1 at baseline.

         12. Uncontrolled intercurrent illness including, but not limited to uncontrolled active
             infection, clinically significant non-healing or healing wounds, symptomatic
             congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia,
             significant pulmonary disease, uncontrolled infection, or psychiatric illness/social
             situations that would limit compliance with study requirements.

         13. Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

         14. History of posterior reversible encephalopathy syndrome

         15. Enrollment on any additional investigational agent study

         16. Known hypersensitivity to gemcitabine or taxanes

         17. Significant cardiac disease including the following: unstable angina, New York Heart
             Association class III-IV congestive heart failure, myocardial infarction < 6 months
             prior to study enrollment

         18. History of hemolytic-uremic syndrome

         19. Known infection with Human Immunodeficiency Virus (HIV) and/or active infection with
             hepatitis B or hepatitis C